Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Neuronetics, Inc.NASDAQ: STIM

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q1 FY2026 financing cash flow was -$5.58M, compared with $18.98M a year earlier. Trailing-twelve-month financing cash flow was $11.3M. Over 3 fiscal years it compounded at +457.4% a year.

Context

  • Financing cash flow amounted to 24.0% of revenue in FY2025, up 14.9 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near -$5.58M or moves back toward the trailing-twelve-month quarterly average of $2.82M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.58M+442.0% QoQ
Last fiscal yearDec 2025
$35.85M+626.6% YoY
LTMMar 2026
$11.3M-7.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-129.4%——
1 year+626.6%——
3-year CAGR+457.4%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
35.85M USD
Year-over-year change
+626.6%
4-year CAGR
-18.9%

Financing Cash Flow vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.2% is the 6th highest of 9, against a peer median of +23.7%.
  • Financing cash flow amounts to 7.4% of revenue for STIM, versus a peer median of 96.4%.
STIM Competitors
Financing Cash Flow for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$164.7M USD+23.8%+468.8%26649.8%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$89.31M USD+520.7%-5.8%258.5%
PROFProfound Medical Corp.LTM Mar 2026$42.24M USD+23.6%+81.2%223.8%
NYXHNyxoah S.A.LTM Mar 2026€38.51M EUR-50.0%—236.0%
OABIOmniAb, Inc.LTM Mar 2026$27.87M USD+110.1%-36.8%96.4%
CDXSCodexis, Inc.LTM Mar 2026$26.83M USD-17.0%—34.4%
PREPrenetics Global LimitedLTM Mar 2026$24.27M USD—-36.0%21.3%
OSUROraSure Technologies, Inc.LTM Mar 2026$22.27M USD+481.2%-83.6%19.7%
STIMNeuronetics, Inc.LTM Mar 2026$11.3M USD-7.2%+457.4%7.4%
ATLNAtlantic International Corp.LTM Dec 2025$3.87M USD-28.2%—0.9%
Peer median (excluding STIM) —+23.7%-20.9%96.4%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.19M)(37.16M)(30.19M)(43.73M)(39.14M)
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
Deferred Income Tax00000
Stock-Based Compensation7.87M8.75M7.32M5.6M6.85M
Change in Working Capital(6.64M)(5.12M)(14.1M)(6.81M)6.58M
Accounts Receivables(3.05M)(6.66M)(8.83M)(3.73M)3.54M
Inventory(3.44M)(2.59M)(1.1M)3.15M(395K)
Accounts Payables276K(1.97M)2.03M(1.99M)(1.75M)
Other Working Capital(415K)6.1M(6.2M)(4.25M)5.18M
Other Non-Cash Items918K1.14M2.93M11.86M1.87M
Operating Cash Flow(27.98M)(30.74M)(32.04M)(31M)(20.37M)
Capital Expenditures(2.35M)(3.27M)(2.37M)(1.47M)(801K)
Acquisitions (Net)000(2.55M)0
Purchases of Investments00000
Sales of Investments324K000(31K)
Other Investing Activities(7.81M)10M1.05M1.61M31K
Investing Cash Flow(9.84M)6.73M(1.32M)(2.41M)(801K)
Debt Repayment0023.8M(2.52M)9.62M
Common Stock Issued80.97M00026.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.03M207K(1.1M)(4.29M)(594K)
Financing Cash Flow83.01M207K22.7M(6.81M)35.85M
Effect of Forex Changes00000
Net Change in Cash45.18M(23.8M)(10.66M)(40.22M)14.68M
Free Cash Flow(30.34M)(34.01M)(34.41M)(32.46M)(21.18M)

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.